Sibğatullah Ali Orak

Sibğatullah Ali Orak

Auto-generated profile, based on publicly available information

Sibğatullah Ali Orak

Department of Pediatric Neurology, Manisa Celal Bayar University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2024 in Journal of Child Neurology
Verified
Journal Article
Closed access
HAHalil Ural Aksoy
Halil Ural Aksoy
CYCelil Yılmaz
Celil Yılmaz
SOSibgatullah Ali Orak
Sibgatullah Ali Orak
SASenem Ayça
Senem Ayça
MPMuzaffer Polat
Muzaffer Polat
Introduction: A number of biomarkers are used to evaluate the duration of the epileptic seizure and the interictal period following neuronal injury. Invasive diagnostic methods are increasingly being replaced by peripheral or minimally invasive biomarkers that give results faster and are more secure. Purpose: We aimed to evaluate serum glial fibrillary acidic protein (GFAP), S100B, and ubiquitin C-terminal hydrolase (UCHL-1) levels in children with epilepsy. Methods: Our study included 3 groups: a nonrefractory epilepsy group, a refractory epilepsy group, and a control group. The GFAP, S100B, and UCHL-1 levels in serum samples collected 2-24 hours after the last seizure were analyzed using enzyme-linked immunosorbent assays. Results: A total of 69 children participated in the study, with 35 participants in the refractory epilepsy group, 18 in the nonrefractory epilepsy group, and 16 in the control group. The GFAP values in the refractory (25.4 ng/mL) and nonrefractory (26.1 ng/mL) epilepsy groups were found to be statistically significantly higher than those in the control group (17.9 ng/mL; P = .001). The S100B values were found to be significantly higher in the refractory epilepsy group (34.13 pg/mL) than in both the control group and the nonrefractory epilepsy group (28.05 pg/mL; P = .028). No significant differences were observed in the UCHL-1 levels between the 3 groups. Conclusions: We conclude that the observed differences may be due to the increased expression of S100B and GFAP caused by increased and repetitive neuronal damage in refractory epilepsies compared with nonrefractory epilepsies.


2 June 2025 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Open access
SOSibğatullah Ali Orak
Sibğatullah Ali Orak
MPMuzaffer Polat
Muzaffer Polat
MPMert Pak
Mert Pak
ÇKÇisil Çerçi Kubur
Çisil Çerçi Kubur
AAAslı Kübra Atasever
Aslı Kübra Atasever
BÖBeyhan Cengiz Özyurt
Beyhan Cengiz Özyurt
Objective: The objective of this study was to examine the serum levels of vasoactive neuropeptides (calcitonin gene‐related peptide [CGRP], pituitary adenylate cyclase‐activating peptide‐38 [PACAP‐38], substance P [SP], and vasoactive intestinal peptide [VIP], which have been linked to the pathophysiology of migraine in adults) in pediatric migraine without aura during both pain attacks and pain‐free periods and in a control group, with a view of evaluating their diagnostic value in pediatric migraine. Background: The diagnosis of migraine is based on clinical features described by patients and pediatric patients may not be able to express migraine symptoms as clearly as adults. The fact that objective biological markers of migraine have not yet been fully defined makes diagnosis difficult, especially in children. Methods: This prospective cross‐sectional case–control study included 39 children and adolescents (aged 8–18 years) diagnosed with migraine without aura and 40 healthy control children between May 2022 and March 2023. The 39 patients with migraine were evaluated both during the course of their migraine attacks and during periods of pain‐free status. Plasma vasoactive peptides were measured using an enzyme‐linked immunosorbent assay. Results: The comparison of serum SP, PACAP‐38, and CGRP neuropeptide levels in the 39 patients with migriane during the ictal and interictal periods revealed no significant differences between the two periods. VIP neuropeptide levels in the ictal period (mean [standard deviation, SD] 291.6 [118.5] pg/mL) in the migraine cohort were found to be significantly higher than the levels observed in both the interictal (mean [SD] 263.6 [100.9] pg/mL, p = 0.019) and healthy control groups (mean [SD] 229.7 [109.3] pg/mL, p = 0.018) ( p < 0.05). The level of the neuropeptide SP (mean [SD] 150.5 [29] pg/mL) in the interictal period was found to be lower than that observed in the healthy control group (mean [SD] 174.6 [39.4] pg/mL, p = 0.030) ( p < 0.05). Furthermore, the CGRP level in the interictal period (mean [SD] 395.6 [197.6] pg/mL) was found to be significantly higher than that observed in the healthy control group (mean [SD] 320.3 [126.6] pg/mL, p = 0.049) ( p < 0.05). No significant differences were observed in the levels of the other neuropeptides. Conclusions: The present study revealed elevated VIP levels during the ictal period and elevated CGRP levels during the interictal period in patients with migraine without aura when compared to controls. In addition, VIP serum levels were significantly higher in the ictal period compared to both the interictal period and healthy controls. The findings of our study lend support to the use of these neuropeptides as biomarkers for migraine. Nevertheless, further studies and standardization are necessary to ascertain the diagnostic value of single or combinations of SP, PACAP‐38, VIP, and CGRP neuropeptides in diagnosing pediatric migraine and differentiating pediatric migraine from non‐migraine headaches.

21 March 2023 in Archives de Pédiatrie
Verified
Journal Article
Closed access
SOSibğatullah Ali Orak
Sibğatullah Ali Orak
ÇKÇisil Çerçi Kubur
Çisil Çerçi Kubur
AAAslı Kübra Atasever
Aslı Kübra Atasever
MPMuzaffer Polat
Muzaffer Polat

31 December 2021 in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
Verified
Journal Article
Closed access
ÇKÇisil Çerçi̇ Kubur
Çisil Çerçi̇ Kubur
AAAslı Kübra ATASEVER
Aslı Kübra ATASEVER
CYCelil Yilmaz
Celil Yilmaz
SOSibğatullah Ali ORAK
Sibğatullah Ali ORAK
MPMuzaffer Polat
Muzaffer Polat
Epileptik ensefalopatiler (EE), çoklu nöbet tipleri, gelişimsel gecikme ve hatta gerileme ile karakterize ciddi epilepsi sendromlarıdır. CHD2'deki (kromodomain sarmal DNA bağlayıcı protein 2) patojenik varyantlar, epileptik ensefalopatilerde ve ayrıca zihinsel engellilikten atonik-miyoklonik epilepsiye kadar değişen fenotipik değişkenlik spektrumuna sahip nörogelişimsel bozukluklarda bildirilmiştir. Biz bu olgu sunumunda oğul, erkek kardeş ve anneden oluşan kalıtsal bir patojenik CHD2 varyantı ailesini rapor ediyoruz. Bu vaka, aile içinde aynı CHD2 mutasyonu ile oluşan fenotipik heterojeniteyi gösterir ve CHD2 ile ilişkili nörogelişimsel bozuklukların potansiyel kalıtsallığını doğrular.

10 May 2024 in Molecular Syndromology
Verified
Journal Article
Closed access
PDF file
SOSibğatullah Ali Orak
Sibğatullah Ali Orak
DBDilek Gün Bilgiç
Dilek Gün Bilgiç
ÇKÇisil Çerçi Kubur
Çisil Çerçi Kubur
AAAslı Kübra Atasever
Aslı Kübra Atasever
CYCelil Yılmaz
Celil Yılmaz
MPMuzaffer Polat
Muzaffer Polat
Introduction: As with many genetic diseases, the diagnostic role of next-generation sequencing is invaluable for early-onset epileptic encephalopathies. SNARE proteins in synaptic vesicles (synaptobrevin-2) and synaptic plasma membrane (syntaxin-1, SNAP-25) are involved in synaptic exocytosis and recycling. Patient Presentation: Here, we report a patient that started in early childhood with seizures resistant to antiepileptic drugs, then developed epileptic encephalopathy. Discussion/Conclusion: The NAPB gene encodes proteins in the SNARE complex. A previously unidentified homozygous missense variant in the NAPB gene may have contributed significantly to the etiology of our patient with epileptic encephalopathy. We also summarize the clinical, radiological, laboratory, and genetic findings of previously published patients with NAPB variants.